<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01185405</url>
  </required_header>
  <id_info>
    <org_study_id>AVORI</org_study_id>
    <nct_id>NCT01185405</nct_id>
  </id_info>
  <brief_title>Voriconazole Plasma Level in Intensive Care Unit (ICU) Patients</brief_title>
  <official_title>Prediction and Adjustment of Voriconazole Plasma Level in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Voriconazole, a newer triazole-derivative, has become the drug of choice for many invasive
      fungal infections, including invasive Aspergillosis. Recently, therapeutic drug monitoring of
      voriconazole has been issued because of wide variations and unpredictability of voriconazole
      blood concentration. The objective of this study is 1) to characterize the pharmacokinetics
      of voriconazole in ICU patients on voriconazole prophylaxis or treatment, and 2) to develop
      and evaluate the prediction and adjustment models for voriconazole plasma levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomly assigned into 2 groups: conventional adjustment group (CA group)
      and early adjustment group (EA group). Voriconazole plasma levels will be measured on day 1
      (both peak and trough levels), day 3, day 5, day 10, and day 14 (all trough levels). For CA
      group patients, voriconazole dosage will be adjusted according to the trough levels of day 5
      (steady-state level). Predefined dose adjustment protocol will be used (&lt; 1 µg/ml: 50%
      increase, 1~5.5 µg/ml: no change, &gt; 5.5 µg/ml: 50% decrease). For EA group patients,
      voriconazole dosage will be adjusted according to the each measurements of voriconazole
      levels from day 1. Adjusted dosage will be calculated using the NONMEN software. The target
      range of trough level is between 1.0 µg/ml and 5.5 µg/ml. The appropriateness of voriconazole
      level (day 5, day 10, and day 14), mortality, ICU stay, and the frequency of
      voriconazole-related adverse events will be compared. CYP2C19 polymorphism will be analyzed
      for all patients.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Appropriateness of voriconazole trough level</measure>
    <time_frame>Day 3, day 5, day 10, and day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>2 week, 4 week, 8 week, 12 week, and 24 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voriconazole-related adverse event</measure>
    <time_frame>1 week, 2 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Invasive Fungal Infection</condition>
  <arm_group>
    <arm_group_label>EA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Voriconazole dosage adjustment according to the each measurements of voriconazole levels from day 1, using NONMEM program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CA group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Voriconazole dosage adjustment according to the levels from day 5, using predefined protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Use of different strategy for voriconazole dosage adjustment</intervention_name>
    <description>Patients will be randomly assigned into 2 groups: conventional adjustment group (CA group) and early adjustment group (EA group). Voriconazole plasma levels will be measured on day 1 (both peak and trough levels), day 3, day 5, day 10, and day 14 (all trough levels). For CA group patients, voriconazole dosage will be adjusted according to the trough levels of day 5 (steady-state level). Predefined dose adjustment protocol will be used (&lt; 1 µg/ml: 50% increase, 1~5.5 µg/ml: no change, &gt; 5.5 µg/ml: 50% decrease). For EA group patients, voriconazole dosage will be adjusted according to the each measurements of voriconazole levels from day 1. Adjusted dosage will be calculated using the NONMEN software.</description>
    <arm_group_label>EA group</arm_group_label>
    <arm_group_label>CA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who received voriconazole

        Exclusion Criteria:

          -  Patients allergic to azole(s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Ho Choi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2010</study_first_submitted>
  <study_first_submitted_qc>August 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2010</study_first_posted>
  <last_update_submitted>September 29, 2013</last_update_submitted>
  <last_update_submitted_qc>September 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sang-Ho Choi</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Voriconazole</keyword>
  <keyword>Therapeutic drug monitoring</keyword>
  <keyword>Intensive care unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

